Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study

Authors

Swaminathan Iyer

Published

November 1, 2024

Abstract

Supporters

Support the authors with ResearchCoin

Journal

The Lancet Oncology

Topics

DOI

10.1016/s1470-2045(24)00508-4

Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study

Authors

Swaminathan Iyer

Published

November 1, 2024

Abstract

Supporters

Support the authors with ResearchCoin

Journal

The Lancet Oncology

Topics

DOI

10.1016/s1470-2045(24)00508-4

Paper

Paper

Paper

Paper

Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study

Abstract

Supporters

Journal

Topics

DOI

Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study

Abstract

Supporters

Journal

Topics

DOI